302 related articles for article (PubMed ID: 22163003)
21. Expression of BRAF V600E mutant protein in epithelial ovarian tumors.
Preusser M; Capper D; Berghoff AS; Horvat R; Wrba F; Schindl M; Schoppmann SF; von Deimling A; Birner P
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):159-64. PubMed ID: 22820660
[TBL] [Abstract][Full Text] [Related]
22. BRAF
Turashvili G; Grisham RN; Chiang S; DeLair DF; Park KJ; Soslow RA; Murali R
Histopathology; 2018 Sep; 73(3):438-443. PubMed ID: 29770477
[TBL] [Abstract][Full Text] [Related]
23. Different proportions of aneusomic cells in ovarian inclusion cysts associated with serous borderline tumours and serous high-grade carcinomas support different pathogenetic pathways.
Körner M; Burckhardt E; Mazzucchelli L
J Pathol; 2005 Sep; 207(1):20-6. PubMed ID: 16021676
[TBL] [Abstract][Full Text] [Related]
24. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
[TBL] [Abstract][Full Text] [Related]
25. The status of epidermal growth factor receptor in borderline ovarian tumours.
Showeil R; Romano C; Valganon M; Lambros M; Trivedi P; Van Noorden S; Sriraksa R; El-Kaffash D; El-Etreby N; Natrajan R; Foroni L; Osborne R; El-Bahrawy M
Oncotarget; 2016 Mar; 7(9):10568-77. PubMed ID: 26870997
[TBL] [Abstract][Full Text] [Related]
26. Oncogenic BRAF and KRAS mutations in endosalpingiosis.
Chui MH; Shih IM
J Pathol; 2020 Feb; 250(2):148-158. PubMed ID: 31576556
[TBL] [Abstract][Full Text] [Related]
27. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.
Vang R; Shih IeM; Kurman RJ
Adv Anat Pathol; 2009 Sep; 16(5):267-82. PubMed ID: 19700937
[TBL] [Abstract][Full Text] [Related]
28. Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma: correlation with tumour progression and nm23 gene expression.
Mandai M; Konishi I; Komatsu T; Mori T; Arao S; Nomura H; Kanda Y; Hiai H; Fukumoto M
Br J Cancer; 1995 Sep; 72(3):691-5. PubMed ID: 7669582
[TBL] [Abstract][Full Text] [Related]
29. Molecular characterization of 103 ovarian serous and mucinous tumors.
Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
[TBL] [Abstract][Full Text] [Related]
30. Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa.
Murali R; Selenica P; Brown DN; Cheetham RK; Chandramohan R; Claros NL; Bouvier N; Cheng DT; Soslow RA; Weigelt B; McCluggage WG
Histopathology; 2019 Mar; 74(4):638-650. PubMed ID: 30565721
[TBL] [Abstract][Full Text] [Related]
31. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM
Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779
[TBL] [Abstract][Full Text] [Related]
32. In serous ovarian neoplasms the frequency of Ki-ras mutations correlates with their malignant potential.
Haas CJ; Diebold J; Hirschmann A; Rohrbach H; Löhrs U
Virchows Arch; 1999 Feb; 434(2):117-20. PubMed ID: 10071245
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression.
Nilforoushan N; Moatamed NA
Ann Diagn Pathol; 2020 Oct; 48():151582. PubMed ID: 32866902
[TBL] [Abstract][Full Text] [Related]
34. Mutational analysis of KRAS, BRAF, and TP53 genes of ovarian serous carcinomas in Korean women.
Cho YH; Kim DY; Kim JH; Kim YM; Kim KR; Nam JH; Kim YT
Yonsei Med J; 2009 Apr; 50(2):266-72. PubMed ID: 19430562
[TBL] [Abstract][Full Text] [Related]
35. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics.
Prat J; D'Angelo E; Espinosa I
Hum Pathol; 2018 Oct; 80():11-27. PubMed ID: 29944973
[TBL] [Abstract][Full Text] [Related]
36. Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.
Sangha N; Wu R; Kuick R; Powers S; Mu D; Fiander D; Yuen K; Katabuchi H; Tashiro H; Fearon ER; Cho KR
Neoplasia; 2008 Dec; 10(12):1362-72, following 1372. PubMed ID: 19048115
[TBL] [Abstract][Full Text] [Related]
37. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling.
Gilks CB; Vanderhyden BC; Zhu S; van de Rijn M; Longacre TA
Gynecol Oncol; 2005 Mar; 96(3):684-94. PubMed ID: 15721412
[TBL] [Abstract][Full Text] [Related]
38. Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions.
Emerson RE; Wang M; Liu F; Lawrence WD; Abdul-Karim FW; Cheng L
Int J Gynecol Pathol; 2007 Oct; 26(4):387-94. PubMed ID: 17885488
[TBL] [Abstract][Full Text] [Related]
39. Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers.
Sadlecki P; Walentowicz P; Bodnar M; Marszalek A; Grabiec M; Walentowicz-Sadlecka M
Tumour Biol; 2017 May; 39(5):1010428317706230. PubMed ID: 28488545
[TBL] [Abstract][Full Text] [Related]
40. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]